PA
DYN icon

Profund Advisors’s Dyne Therapeutics DYN Stock Holding History

Profund Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
58,810
-23,328
-28% -$434K 0.04% 291
2026
Q1 		$1.49M Sell
82,138
-4,608
-5% -$79.5K 0.05% 250
2025
Q4 		$1.7M Buy
86,746
+40,766
+89% +$772K 0.05% 249
2025
Q3 		$582K Buy
45,980
+22,338
+94% +$255K 0.02% 465
2025
Q2 		$225K Sell
23,642
-7,077
-23% -$77.9K 0.01% 834
2025
Q1 		$321K Sell
30,719
-1,875
-6% -$26.8K 0.01% 641
2024
Q4 		$768K Sell
32,594
-298
-0.9% -$8.81K 0.03% 353
2024
Q3 		$1.18M Buy
32,892
+5,471
+20% +$218K 0.04% 287
2024
Q2 		$968K Sell
27,421
-26,026
-49% -$756K 0.04% 306
2024
Q1 		$1.52M Buy
53,447
+26,485
+98% +$599K 0.06% 225
2023
Q4 		$359K Buy
26,962
+3,169
+13% +$31K 0.02% 687
2023
Q3 		$213K Buy
23,793
+2,131
+10% +$23K 0.01% 850
2023
Q2 		$244K Buy
+21,662
New +$256K 0.01% 848

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Profund Advisors's DYN Position: Q2 2026 in Review

Profund Advisors reduced its Dyne Therapeutics (DYN) stake by 28% in Q2 2026, selling an estimated $434K and leaving 58,810 shares worth $1.31M. The position accounts for 0.04% of the portfolio, ranked #291.

Profund Advisors first reported a position in DYN in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.7M in Q4 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Profund Advisors held 58,810 shares of Dyne Therapeutics worth $1.31M as of Q2 2026.
  • Profund Advisors sold 23,328 Dyne Therapeutics shares in Q2 2026, an estimated $434K.
  • Dyne Therapeutics made up 0.04% of Profund Advisors's portfolio in Q2 2026, its #291 holding.
  • Profund Advisors first reported a position in Dyne Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • Profund Advisors's Dyne Therapeutics position peaked at $1.7M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.